頁籤選單縮合
題名 | A Booster Dose of Delta ╳ Omicron Hybrid mRNA Vaccine Produced Broadly Neutralizing Antibody against Omicron and Other SARS-CoV-2 Variants |
---|---|
作者 | Lee, I-jung; Sun, Cheng-pu; Wu, Ping-yi; Lan, Yu-hua; Wang, I-hsuan; Liu, Wen-chun; Yuan, Joyce Pei-yi; Chang, Yu-wei; Tseng, Sheng-che; Tsung, Szu-i; Chou, Yu-chi; Kumari, Monika; Lin, Yin-shiou; Chen, Hui-feng; Chen, Tsung-yen; Lin, Chih-chao; Chiu, Chi-wen; Hsieh, Chung-hsuan; Chuang, Cheng-ying; Cheng, Chao-min; Lin, Hsiu-ting; Chen, Wan-yu; Hsu, Fu-fei; Hong, Ming-hsiang; Liao, Chun-che; Chang, Chih-shin; Liang, Jian-jong; Ma, Hsiu-hua; Chiang, Ming-tsai; Liao, Hsin-ni; Ko, Hui-ying; Chen, Liang-yu; Ko, Yi-an; Yu, Pei-yu; Yang, Tzu-jing; Chiang, Po-cheng; Hsu, Shang-te; Lin, Yi-ling; Lee, Chong-chou; Wu, Han-chung; Tao, Mi-hua; | 書刊名 | Journal of Biomedical Science |
卷期 | 29 2022[民111] |
頁次 | 頁(49)1-(49)13 |
分類號 | 418.293 |
關鍵詞 | Omicron vaccine; mRNA vaccine; SARS-CoV-2; COVID-19; Variants of concern; Hybrid vaccine; Booster dose; Next generation vaccine; Cross-protectivity; |
語文 | 英文(English) |
DOI | 10.1186/s12929-022-00830-1 |
英文摘要 | Background With the continuous emergence of new SARS-CoV-2 variants that feature increased transmission and immune escape, there is an urgent demand for a better vaccine design that will provide broader neutralizing efficacy. Methods We report an mRNA-based vaccine using an engineered “hybrid” receptor binding domain (RBD) that contains all 16 point-mutations shown in the currently prevailing Omicron and Delta variants. Results A booster dose of hybrid vaccine in mice previously immunized with wild-type RBD vaccine induced high titers of broadly neutralizing antibodies against all tested SARS-CoV-2 variants of concern (VOCs). In naïve mice, hybrid vaccine generated strong Omicron-specific neutralizing antibodies as well as low but significant titers against other VOCs. Hybrid vaccine also elicited CD8+/IFN-γ+ T cell responses against a conserved T cell epitope present in wild type and all VOCs. Conclusions These results demonstrate that inclusion of different antigenic mutations from various SARS-CoV-2 variants is a feasible approach to develop cross-protective vaccines. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。